Enabling scalable manufacture of exosomes for future clinical & commercial requirements

Cell & Gene Therapy Insights 2022; 8(10), 1269–1276

DOI: 10.18609/cgti.2022.186

Published: 22 October 2022
Peter Jones

David McCall, Commissioning Editor, Cell & Gene Therapy Insightsspoke to Peter Jones, Vice President of CMC, Evox Therapeutics

Peter Jones has over 30 years of experience in the biopharmaceutical industry and is currently Vice President of CMC at Evox Therapeutics. Prior to this, he was Executive Director, Process Development at Autolus Therapeutics, and held several positions of responsibility at Oxford Biomedica, including Senior Director, Head of Operational Strategy, Head of Technical Operations, and Head of Manufacturing Development. Peter also served in multiple senior roles at GlaxoSmithkline and Genzyme in bioprocess development and manufacturing. Peter has a BSc (Hons) in Applied Biology from the University of Hertfordshire and a MSc (Eng) in Biochemical Engineering from University College, London. He is a Chartered Chemical Engineer, Fellow of the Institution of Chemical Engineers and Royal Academy of Engineering. Visiting Professor in Manufacturing of Advanced Therapies at Aston University.